Phase I/II study of TAS-120

Phase 1

Completed

• Conditions: solid tumors

• Registration Number: JPRN-jRCT2080224117
• Lead Sponsor: Taiho Pharmaceutical Co., Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-10-29
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: completed
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Provide written informed consent.
2. Is >= 20 years.
3. Has histologically or cytologically confirmed, locally advanced, metastatic cancer.
4. Patient has measurable disease.
5. ECOG performance status 0 or 1.
6. Able to take medications orally.
7. Adequate organ function.
8. Have a negative pregnancy test.
9. Willing and able to comply with scheduled visits and study procedures.

Exclusion Criteria

1. History and/or current evidence of non-tumor related alteration of calcium-phosphorus homeostasis.
2. History and/or current evidence of clinically significant ectopic mineralization/calcification.
3. History and/or current evidence of clinically significant retinal disorder confirmed by retinal examination.
4. A serious illness or medical condition(s)

Study & Design

• Study Type: Interventional
• Study Design: Not specified